Clinical trial NCT03882437: Gene Therapy for Male Patients With Danon Disease (DD) Using RP-A501; AAV9.LAMP2B
Official title: A Clinical Study Evaluating a Recombinant Adeno-Associated Virus Serotype 9 (rAAV9) Capsid Containing the Human Lysosome-Associated Membrane Protein 2 Isoform B (LAMP2B) Transgene (RP-A501; AAV9.LAMP2B) in Male Patients With DD
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Danon Disease
Keywords: hypertrophic cardiomyopathy
HCM
X-linked disease
LAMP 2A
Pediatric
Skeletal myopathies
Lead sponsor: Rocket Pharmaceuticals Inc.
Sponsor class: INDUSTRY
First posted: 2019-03-20
Enrollment: 7
Sex: MALE
Minimum age (years): 8
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SEQUENTIAL
Intervention model description: Evaluation of RP-A501 in pediatric patients (ages 8-14) will commence only pending determination of safety in the older (adult and age 15-17) population.

In Phase 1, RP-A501 will be investigated in three treatment cohorts, as follows with a single cohort currently recruiting:

Cohort 1: Adult and age 15-17: 6.7 × 1013 GC/kg (n=3-4)

Cohort 2: Adult and age 15-17: 1.1 × 1014 GC/kg (n=2 \[patients already treated; closed for current enrollment\])

Cohort 1A: Pediatric age 8-14: 6.7 × 1013 GC/kg (n=2-4)
Primary purpose: TREATMENT

Brief summary: This is a non-randomized open-label Phase 1 study to evaluate the safety and toxicity of gene therapy using a recombinant adeno-associated virus serotype 9 (AAV9) containing the human lysosome-associated membrane protein 2 isoform B (LAMP2B) transgene (investigational product (IP), RP-A501) in male patients with Danon Disease (DD).

Detailed description: The study is a non-randomized open-label Phase I clinical trial to characterize the safety and toxicity associated with infusion of a recombinant adeno-associated serotype 9 (rAAV9) capsid containing the human lysosome-associated membrane protein 2 isoform B (LAMP2B) transgene (investigational product (IP), RP-A501) in male patients with Danon Disease (DD).

During the course of the study, approximately 7-10 male subjects age 8 and over will receive a single intravenous (IV) infusion of the IP. Prior to infusion of IP, rituximab and sirolimus will be administered prophylactically.

All patients are planned to be followed for 36 months after investigational product administration. After the end of the follow-up period, patients will enter a Long-Term Follow-Up (LTFU) study enabling follow-up for an additional 2 to 5 years post-IP administration.

The study will also enable an initial evaluation of whether or not the IP results in cardiomyocyte and skeletal muscle transduction and gene expression and preliminary assessment of the extent of cardiomyocyte and histologic correction. Additionally, a preliminary evaluation of clinical stabilization following infusion will also be made.

Eligibility criteria: Main Criteria for Inclusion:

The study will enroll adult and pediatric males with a confirmed diagnosis of DD. Patients may be of any race or ethnicity. Patients and/or competent custodial parents must provide informed written consent and meet all of the enrollment criteria as detailed subsequently to be eligible to participate.

1. DD diagnosis with any confirmed LAMP2 mutation(s).
2. Cardiac involvement as documented by at least one abnormal finding on electrocardiogram (ECG), echocardiogram, gadolinium-enhanced cardiac magnetic resonance imaging (MRI), or electrophysiology study.
3. Age ≥15 years for cohorts 1 and 2; 8-14 years for cohorts 1A.
4. Male gender.
5. New York Heart Association (NYHA) Class II or III.
6. Adequate hematologic function as defined by hemoglobin, absolute neutrophil count (ANC), and platelet count ≥ lower limit of normal (LLN).
7. Adequate hepatic function as defined by:

   1. AST and ALT ≤10.0×ULN or GGT ≤2.0×ULN (transaminase elevations in DD are considered extensively to result from muscle injury; hence the relatively high upper limit for transaminases and consideration of GGT level, and the presence of additional hepatic eligibility markers of bilirubin and PT/INR).
   2. Serum bilirubin ≤1.2×ULN (i.e., Grade ≤1 bilirubin increase).
   3. PT/INR ≤1.2×ULN (in the absence of anticoagulation).
   4. Absence of cirrhosis or other signs of inflammation on liver ultrasound
8. Adequate renal function as defined by creatinine ≤ULN.
9. Ability to provide informed consent (for adult patients and parents/legal guardians of pediatric patients) and assent (for patients age 15-17).
10. Ability to comply with study procedures including investigational therapy and follow-up evaluations.
11. Able to walk \>150 meters unassisted during the 6MWT.
12. Patient has received meningococcal vaccination recommended by Centers for Disease Control as appropriate for age and health condition (vaccination must be performed at least 6 weeks prior to IP administration).

Main Criteria of Exclusion:

Patients meeting any of the following criteria are not eligible for study participation:

1. I.V. therapy with positive inotropes, vasodilators, or diuretics within the 30 days prior to enrollment (i.e., patient must be stable on oral medical therapy).
2. Prior cardiac transplantation or prior transplant of other organ (lung, liver, other).
3. Prior cardiac surgery and/or percutaneous cardiac intervention for arteriothrombotic complications, or valvuloplasty.
4. Presence or requirement of a Left Ventricular Assisted Device (LVAD).
5. History of intracardiac thrombosis or arteriothromboembolic events including stroke or transient ischemic attack (TIA).
6. Left ventricular ejection fraction (LVEF) \<40% at baseline.
7. History of the following prior arteriothromboembolic complications: myocardial infarction or unstable angina.
8. Significant (greater than moderate) valvular stenosis or regurgitation on echocardiogram.
9. Requires mechanical ventilation.
10. Anti-AAV9 neutralizing antibody titer \>1:40.
11. Concurrent enrollment in any other clinical investigation involving use of an investigational agent for the treatment of CHF or cardiomyopathy.
12. Active hepatitis B or C infection (including patients with positive hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), hepatitis B core antibody (HBcAb), or detectable hepatitis B virus (HBV) or hepatitis C virus (HCV) viral load). Patients with previous, adequately resolved HBV or HCV are eligible.
13. Significant medical conditions including documented human immunodeficiency virus (HIV) infection, active viral or other hepatitis, poorly-controlled hypertension or diabetes, poorly controlled cardiac arrhythmia, or uncontrolled viral, bacterial, or fungal infection.
14. Any concomitant medical or psychiatric condition that in the opinion of the Investigator renders the patient unfit for study participation or at higher than acceptable risk for study participation.
15. Active hematologic or solid organ malignancy, not including non-melanoma skin cancer or other carcinoma in situ. Patients with previously resected solid organ malignancies or definitively treated hematologic malignancies may be eligible if there has been no evidence of active malignancy during the prior 3 years.
16. Any contraindication to use of sirolimus which includes hypersensitivity to sirolimus or HC-60 (polyoxyl 60 hydrogenated castor oil).
17. Active or latent tuberculosis.

Primary outcomes:
measure: Number of participants with treatment-related adverse events as assessed by United States (US) National Cancer Institute Common Terminology Criteria (NCI CTCAE)
timeFrame: 3 years
measure: Number of participants within each dose level cohort with treatment-related adverse events as assessed by United States (US) National Cancer Institute Common Terminology Criteria (NCI CTCAE)
timeFrame: 3 years
measure: Evaluation of cardiomyocyte histologic correction following administration of RP-A501 via endomyocardial biopsy
timeFrame: 3 years
measure: Preliminary evaluation of clinical stabilization of cardiomyopathy following administration of RP-A501 via cardiopulmonary testing
timeFrame: 3 years
Secondary outcomes:
measure: Determination of the percentage of patients in whom RP-A501 resulted in a sustained improvement or stabilization in cardiovascular pathophysiology
timeFrame: 3 years
measure: Determination of the percentage of patients in whom cardiomyocytes corrected LAMP2B gene and/or protein
timeFrame: 3 years
measure: Determination and characterization of immunologic response to RP-A501
timeFrame: 3 years
measure: Determination of the percentage of patients who require and/or receive treatment for heart failure following RP-A501
timeFrame: 3 years
measure: Evaluation of overall survival
timeFrame: 3 years
Other outcomes:
Locations:
city: La Jolla
country: United States
facility: University of California, San Diego
state: California
city: Aurora
country: United States
facility: University of Colorado
state: Colorado
city: Philadelphia
country: United States
facility: Children's Hospital of Philadelphia
state: Pennsylvania
Study officials:
affiliation: Children's Hospital of Philadelphia
name: Joseph Rossano, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Colorado, Anschutz Medical Ctr
name: Matthew Taylor, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: University of California, San Diego
name: Barry Greenberg, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: O'Neil EC, Uyhazi KE, O'Connor K, Aleman IA, Pulido JS, Rossano JW, Aleman TS. DANON DISEASE: A MODEL OF PHOTORECEPTOR DEGENERATION SECONDARY TO PRIMARY RETINAL PIGMENT EPITHELIUM DISEASE. Retin Cases Brief Rep. 2022 Nov 1;16(6):707-713. doi: 10.1097/ICB.0000000000001125.